Showing results (261-270 of 293) with videos related to

Sort By:
Pageof 30
Practical Radiation Oncology|February 4, 2024
Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year ExperienceBrianna Conte, Dana L Casey, Kathryn R Tringale, et al.
Pediatric Blood & Cancer|September 24, 2017
A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastomaKim Kramer, Neeta Pandit-Taskar, John L Humm, et al.
British Journal of Haematology|January 14, 2026
Prognostic role of PET/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL GroupS Claire Gowdy, Jamie E Flerlage, Jennifer Seelisch, et al.
International Journal of Radiation Oncology, Biology, Physics|October 21, 2025
Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical TrialChristopher B Jackson, Dana L Casey, Brian H Kushner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.
Research Square|November 21, 2023
Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cellsMaxim Yankelevich, Archana Thakur, Shakeel Modak, et al.
Pediatric Blood & Cancer|December 31, 2016
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumorsOren J Becher, Stephen W Gilheeney, Yasmin Khakoo, et al.
Journal of Pediatric Surgery|October 6, 2010
Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infectionsMark L Kayton, Edward G Garmey, Nicole M Ishill, et al.
Plos Genetics|December 21, 2016
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma GenomeOlivia M Padovan-Merhar, Pichai Raman, Irina Ostrovnaya, et al.
Journal for Immunotherapy of Cancer|March 22, 2024
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cellsMaxim Yankelevich, Archana Thakur, Shakeel Modak, et al.
Pageof 30